Darin J. Falk

Darin J. Falk

Auto-generated profile, based on publicly available information

Darin J. Falk

Pediatrics, University of Florida, Gainesville, FL

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2014 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
DFDarin J. Falk
Darin J. Falk
ATAdrian Gary Todd
Adrian Gary Todd
SLSooyeon Lee
Sooyeon Lee
MSMeghan S. Soustek
Meghan S. Soustek
MEMai K. ElMallah
Mai K. ElMallah
BBBarry J. Byrne
Barry J. Byrne
Pompe disease is a systemic metabolic disorder characterized by lack of acid-alpha glucosidase (GAA) resulting in ubiquitous lysosomal glycogen accumulation. Respiratory and ambulatory dysfunction are prominent features in patients with Pompe yet the mechanism defining the development of muscle weakness is currently unclear. Transgenic animal models of Pompe disease mirroring the patient phenotype have been invaluable in mechanistic and therapeutic study. Here, we demonstrate significant pathological alterations at neuromuscular junctions (NMJs) of the diaphragm and tibialis anterior muscle as prominent features of disease pathology in Gaa knockout mice. Postsynaptic defects including increased motor endplate area and fragmentation were readily observed in Gaa−/− but not wild-type mice. Presynaptic neuropathic changes were also evident, as demonstrated by significant reduction in the levels of neurofilament proteins, and alterations in axonal fiber diameter and myelin thickness within the sciatic and phrenic nerves. Our data suggest the loss of NMJ integrity is a primary contributor to the decline in respiratory and ambulatory function in Pompe and arises from both pre- and postsynaptic pathology. These observations highlight the importance of systemic phenotype correction, specifically restoration of GAA to skeletal muscle and the nervous system for treatment of Pompe disease.

29 April 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ATAdrian G. Todd
Adrian G. Todd
JMJessica A. McElroy
Jessica A. McElroy
RGRobert W. Grange
Robert W. Grange
DFDavid D. Fuller
David D. Fuller
GWGlenn A. Walter
Glenn A. Walter
DFDarin J. Falk
Darin J. Falk

4 November 2015 in Human Gene Therapy
Verified
Journal Article
Closed access
PDPhillip A. Doerfler
Phillip A. Doerfler
ATAdrian G. Todd
Adrian G. Todd
NCNathalie Clément
Nathalie Clément
DFDarin J. Falk
Darin J. Falk
SNSushrusha Nayak
Sushrusha Nayak
BBBarry J. Byrne
Barry J. Byrne
Pompe disease is a progressive neuromuscular disorder caused by lysosomal accumulation of glycogen from a deficiency in acid alpha-glucosidase (GAA). Replacement of the missing enzyme is available by repeated protein infusions; however, efficacy is limited by immune response and inability to restore enzymatic function in the central nervous system. An alternative therapeutic option is adeno-associated virus (AAV)-mediated gene therapy, which results in widespread gene transfer and prolonged transgene expression. Both enzyme replacement therapy (ERT) and gene therapy can elicit anti-GAA immune reactions that dampen their effectiveness and pose life-threatening risks to patient safety. To modulate the immune responses related to gene therapy, we show that a human codon-optimized GAA (coGAA) driven by a liver-specific promoter (LSP) using AAV9 is capable of promoting immune tolerance in a Gaa −/− mouse model. Copackaging AAV9-LSP-coGAA with the tissue-restricted desmin promoter (AAV9-DES-coGAA) demonstrates the necessary cell autonomous expression in cardiac muscle, skeletal muscle, peripheral nerve, and the spinal cord. Simultaneous high-level expression in liver led to the expansion of GAA-specific regulatory T-cells (T regs ) and induction of immune tolerance. Transfer of T regs into naïve recipients prevented pathogenic allergic reactions after repeated ERT challenges. Copackaged AAV9 also attenuated preexisting humoral and cellular immune responses, which enhanced the biochemical correction. Our data present a therapeutic design in which simultaneous administration of two copackaged AAV constructs may provide therapeutic benefit and resolve immune reactions in the treatment of multisystem disorders.

18 June 2012 in Genetic Vaccines and Therapy
Verified
Journal Article
Open access
PDF file
NLNi-Chung Lee
Ni-Chung Lee
DFDarin J Falk
Darin J Falk
BBBarry J Byrne
Barry J Byrne
TCThomas J Conlon
Thomas J Conlon
NCNathalie Clement
Nathalie Clement
WHWuh-Liang Hwu
Wuh-Liang Hwu
The appropriate tropism of adeno-associated virus (AAV) vectors that are systemically injected is crucial for successful gene therapy when local injection is not practical. Acidic oligopeptides have been shown to enhance drug delivery to bones. In this study six-L aspartic acids (D6) were inserted into the AAV2 capsid protein sequence between amino acid residues 587 and 588. 129SVE mice were injected with double-stranded wild-type- (WT-) or D6-AAV2 mCherry expression vectors (3.24 x 1010 vg per animal) via the superficial temporal vein within 24 hours of birth. Fluorescence microscopy and quantitative polymerase chain reaction confirmed higher levels of mCherry expression in the paraspinal and gluteus muscles in the D6-AAV2 injected mice. The results revealed that although D6-AAV2 was less efficient in the transduction of immortalized cells stronger mCherry signals were detected over the spine and pelvis by live imaging in the D6-AAV2-injected mice than were detected in the WT-AAV2-injected mice. In addition, D6-AAV2 lost the liver tropism observed for WT-AAV2. An acidic oligopeptide displayed on AAV2 improves axial muscle tropism and decreases liver tropism after systemic delivery. This modification should be useful in creating AAV vectors that are suitable for gene therapy for diseases involving the proximal muscles.

1 May 2015 in Molecular Therapy
Verified
Journal Article
Open access
DFDarin J. Falk
Darin J. Falk
MSMeghan S. Soustek
Meghan S. Soustek
ATA. Gary Todd
A. Gary Todd
CMCathryn S. Mah
Cathryn S. Mah
DCDenise A. Cloutier
Denise A. Cloutier
BBBarry J. Byrne
Barry J. Byrne
Cardiac dysfunction and respiratory muscle weakness are primary features in patients with early onset Pompe disease. To reduce the progressive and rapid accumulation of glycogen resulting in cardiorespiratory dysfunction, adult Gaa-/- mice were administered a single systemic injection of rAAV2/9-DES-hGAA (AAV9) or bi-monthly injections of recombinant human GAA (ERT). Cardiac function and morphology was assessed one and three months after initiation of treatment while whole-body plethysmography and diaphragmatic contractile function was evaluated at three months post-treatment in all groups. Gaa-/- animals receiving either AAV9 or ERT demonstrated a significant improvement in cardiac function and diaphragmatic contractile function as compared to control animals. AAV9 treatment resulted in a significant reduction in cardiac dimension (end diastolic left ventricular mass/gram wet weight; EDMc) at three months post-injection. Neither AAV9 nor ERT therapy altered minute ventilation during quiet breathing (eupnea). However, breathing frequency and expiratory time were significantly improved in AAV9 animals. Glycogen deposition was significantly elevated in Gaa-/- and ERT but not AAV9 when compared to control animals. These results indicate systemic delivery of either strategy improves cardiac function but improvement in respiratory parameters and glycogen reduction are limited to AAV9 therapy at three-months post treatment in a murine model of Pompe disease.

1 May 2015 in Molecular Therapy
Verified
Journal Article
Open access
ATAdrian G. Todd
Adrian G. Todd
JMJessica A. McElroy
Jessica A. McElroy
RGRobert W. Grange
Robert W. Grange
DFDavid D. Fuller
David D. Fuller
GWGlenn A. Walter
Glenn A. Walter
DFDarin J. Falk
Darin J. Falk
We have recently reported pathology of the neuromuscular junction (NMJ) in Pompe disease, reflecting disruption of neuronal and muscle homeostasis as a result of glycogen accumulation. The objective of this study was to examine how alterations of the NMJ contribute to Pompe disease pathology. An AAV9 vector encoding GAA (AAV9-hGAA) was injected directly into the tibialis anterior muscle of Gaa-/- mice at early- mid- and severe- pathological time points. Gene expression of NMJ-related genes, in situ muscle force production, clearance of glycogen in conjunction with histological assessment of the NMJ was subsequently performed in all animals. Our data demonstrate that AAV9-hGAA is able to replace GAA to the affected tissue and modify AChR mRNA expression, muscle force production, motor endplate expansion and innervation status of the NMJ. The degree of restoration for these outcomes is limited by progression of neural pathology. Early restoration of GAA activity in muscle and neural cells was most effective, while late correction of GAA expression was not effective in modifying parameters reflecting NMJ structure and function nor in force restoration despite resolution of glycogen storage in muscle. Our data provide new mechanistic insight into the pathology of Pompe disease and suggest that early systemic correction to both neuronal and muscle tissues may be essential for successful correction of neuromuscular function in Pompe disease.